Clinical trials have shown phentolamine mesylate (PM), brand name OraVerse, to be effective
at reducing the amount of time to reversal of local anesthesia with different dental
anesthetics. However, to date no study investigated the efficacy of phentolamine mesylate to
reverse anesthesia induced with the use of Bupivacaine.
The objective of the proposed research is to conduct a pilot-scale randomized clinical trial
evaluating the difference in time required for the return of normal soft-tissue sensation and
function in participants who have received 0.5% Bupivacaine HCl, 1:200,000 epinephrine,
followed by an injection with either 1) OraVerse (phentolamine mesylate) or 2) sterile
physiological water (control).